Trial Profile
A Multicenter, Prospective Study to Evaluate the Risk of Hypothyroidism in Pediatric Patients Administered Intravascular Iohexol, Iodixanol, Iopromide, or Ioversol THYROPED
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 22 Apr 2022
Price :
$35
*
At a glance
- Drugs Iodixanol (Primary) ; Iohexol (Primary) ; Iopromide (Primary) ; Ioversol (Primary)
- Indications Cardiovascular disorders
- Focus Adverse reactions
- Acronyms THYROPED
- Sponsors GE Healthcare
- 13 Apr 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 25 Jun 2021 Planned initiation date changed from 1 Mar 2021 to 1 Mar 2022.
- 18 May 2020 Planned initiation date changed from 1 Nov 2019 to 1 Mar 2021.